Literature DB >> 11226062

Pituitary tumours.

J R Davis1, W E Farrell, R N Clayton.   

Abstract

Pituitary tumours are a common type of intracranial neoplasm and, depending on the cell type of origin, have diverse endocrine and reproductive effects. The developmental biology of the different cell types is understood to result from a sequential activation of a cascade of transcription factors, and mutations in these factors result in various forms of hypopituitarism. Tumours in the pituitary gland arise from activation of dominantly acting oncogenes such as gsp, or from loss of function of a series of tumour suppressor genes such as MEN1. Abnormal patterns of DNA methylation may be implicated in the allelic losses that cause tumour suppressor gene silencing. The different clinically recognized types of pituitary tumour are currently treated by medical therapies such as dopamine and somatostatin agonists, surgery or radiotherapy. However, these treatments are not entirely satisfactory and recent advances in gene therapy may offer valuable new therapeutic opportunities for patients with aggressive tumours that fail to respond to traditional approaches.

Entities:  

Mesh:

Year:  2001        PMID: 11226062     DOI: 10.1530/rep.0.1210363

Source DB:  PubMed          Journal:  Reproduction        ISSN: 1470-1626            Impact factor:   3.906


  15 in total

1.  The epidemiology of prolactinomas.

Authors:  Antonio Ciccarelli; Adrian F Daly; Albert Beckers
Journal:  Pituitary       Date:  2005       Impact factor: 4.107

Review 2.  Epidemiology, clinical presentation and diagnosis of non-functioning pituitary adenomas.

Authors:  Georgia Ntali; John A Wass
Journal:  Pituitary       Date:  2018-04       Impact factor: 4.107

3.  Complete evaluation of pituitary tumours in a single tertiary care institution.

Authors:  Dimitrios Askitis; Damianos Tsitlakidis; Nicolle Müller; Albrecht Waschke; Gunter Wolf; Ulrich Alfons Müller; Christof Kloos
Journal:  Endocrine       Date:  2018-03-12       Impact factor: 3.633

4.  Prevalence and incidence of pituitary adenomas: a population based study in Malta.

Authors:  Mark Gruppetta; Cecilia Mercieca; Josanne Vassallo
Journal:  Pituitary       Date:  2013-12       Impact factor: 4.107

Review 5.  Gene therapy for pituitary tumors.

Authors:  Adriana Seilicovich; Daniel Pisera; Sandra A Sciascia; Marianela Candolfi; Mariana Puntel; Weidong Xiong; Gabriela Jaita; Maria G Castro
Journal:  Curr Gene Ther       Date:  2005-12       Impact factor: 4.391

6.  Prevalence of double pituitary adenomas in a surgical series: Clinical, histological and genetic features.

Authors:  F Magri; C Villa; D Locatelli; P Scagnelli; M S Lagonigro; P Morbini; M Castellano; E Gabellieri; M Rotondi; E Solcia; A F Daly; L Chiovato
Journal:  J Endocrinol Invest       Date:  2009-12-01       Impact factor: 4.256

Review 7.  Nonfunctioning pituitary adenomas: the Oxford experience.

Authors:  John A H Wass; Niki Karavitaki
Journal:  Nat Rev Endocrinol       Date:  2009-09       Impact factor: 43.330

8.  Retrospective observational analysis of non-irradiated non-functioning pituitary adenomas.

Authors:  I Karamouzis; R Berardelli; N Prencipe; A Berton; C Bona; G Stura; M Corsico; V Gasco; M Maccario; E Ghigo; S Grottoli
Journal:  J Endocrinol Invest       Date:  2015-07-28       Impact factor: 4.256

Review 9.  Gene expression in prolactinomas: a systematic review.

Authors:  Justin Seltzer; Thomas C Scotton; Keiko Kang; Gabriel Zada; John D Carmichael
Journal:  Pituitary       Date:  2016-02       Impact factor: 4.107

10.  Evaluation of survivin splice variants in pituitary tumors.

Authors:  Joanna Waligórska-Stachura; Mirosław Andrusiewicz; Nadia Sawicka-Gutaj; Marta Kubiczak; Anna Jankowska; Włodzimierz Liebert; Agata Czarnywojtek; Ryszard Waśko; Al Ricardo Blanco-Gangoo; Marek Ruchała
Journal:  Pituitary       Date:  2015-06       Impact factor: 4.107

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.